ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.41) by 39.02 percent. This is a 74.23 percent increase over losses of $(0.97) per share from the same period last year. The company reported quarterly sales of $16.91 million which missed the analyst consensus estimate of $19.01 million by 11.03 percent. This is a 0.71 percent increase over sales of $16.79 million the same period last year.